Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of meetings, deadlines, and the like has quickly returned. You knew this would happen, though, yes? To cope, of course, we are quaffing cups of stimulation — Southern Pecan is our choice today, if you care — and, as always, we invite you to join us. Meanwhile, here are some tidbits that you might find equally stimulating. Have a lovely day and do keep in touch …
The Pharmaceutical Research and Manufacturers of America may adopt new membership rules this week that cause companies that do not spend at least $200 million annually on R&D to leave the trade group, Bloomberg News reports. This would be based on a three-year average. Drug makers will also have to prove that their research spending amounts to at least 10 percent of their global sales.
About the Author Reprints
Assuming that Bloomberg is correct, does that mean no pharma without $2 Billion in sales can join? You need that much to support a 10 per cent R&D spend of $200 million USD. Or, I suppose, you could spend 40% of $500 million USD – that would be hard on the bonus structure though, no?